IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with pretreated low-grade non-Hodgkin's lymphoma.

被引：0
|
作者：
Schwandt, KU [1 ]
Bremer, K [1 ]
机构：
[1] Augusta Kranken Anstalt, Bochum, Germany
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477P
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [41] Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (Rituximab)-treated non-Hodgkin's lymphoma
    Nomura, Shosaku
    Ishii, Kazuyoshi
    Kamitsuji, Yuka
    Uoshima, Nobuhiko
    Ishikawa, Emiko
    Kitayama, Hitoshi
    Hayashi, Kunio
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2007, 13 (02) : 206 - 212
  • [42] Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
    Jensen, M
    Winkler, U
    Manzke, O
    Diehl, V
    Engert, A
    ANNALS OF HEMATOLOGY, 1998, 77 (1-2) : 89 - 91
  • [43] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [44] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma (vol 10, pg 108, 1998)
    White, CA
    MINERVA BIOTECNOLOGICA, 1999, 11 (02) : 160 - 160
  • [45] Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation
    Kaya, H
    Keung, YK
    Case, D
    Cruz, JM
    Perry, JJ
    Radford, JE
    Hurd, DD
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (10) : 544 - 549
  • [46] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Tobinai, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S85 - S90
  • [47] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Kensei Tobinai
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S85 - S90
  • [48] Anti-CD20 antibody IDEC-C2B8 mediated apoptosis can be blocked by inhibition of caspase 3
    Mathas, S
    Bommert, K
    Dörken, B
    Mapara, MY
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 726 - 726
  • [49] Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma
    White, CA
    Larocca, A
    Grillo-López, AJ
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (03): : 95 - 101
  • [50] Anti-CD20 monoclonal antibody (rituximab) for therapy of T-cell/histiocyte-rich large B-cell non-Hodgkin lymphoma
    Park, ES
    Lim, JJ
    Kang, HJ
    Shin, HY
    Ahn, HS
    BLOOD, 2005, 106 (11) : 282B - 282B
12345